

## UNDERTAKING

**TO:** Ontario Securities Commission, as Principal Regulator

**RE:** Undertaking in connection with the short form base shelf prospectus of Medexus Pharmaceuticals Inc. (the “**Issuer**”) dated July 28, 2021 (the “**Prospectus**”)

---

In accordance with Section 4.2(a)(ix) of National Instrument 44-101 – *Short Form Prospectus Distributions* and provided that the Issuer is a “reporting issuer” (as defined in the *Securities Act* (Ontario)) and the conditions of Item 13.4 of Form 44-101F1 - *Short Form Prospectus* (“**44-101F1**”) are not met, the Issuer hereby undertakes, if any debt securities are distributed under the Prospectus and for so long as such debt securities are issued and outstanding, to file the periodic and timely disclosure of any credit supporter similar to the disclosure required under Section 12.1 of Form 44-101F1.

***[Remainder of this page intentionally left blank.]***

**DATED** as of the 28th of July, 2021.

**MEDEXUS PHARMACEUTICALS INC.**

By: (signed) "Marcel Konrad"  
Name: Marcel Konrad  
Title: Chief Financial Officer